Skip to content
Medical Health Aged Care

Get active for your brain health and beat dementia in Ballarat!

Dementia Australia 2 mins read

The 2026 Ballarat Memory Walk & Jog is just weeks away, with the event taking place on Saturday 2 May at Lake Wendouree Gardens.

 

As Dementia Australia’s largest annual fundraising initiative, Memory Walk & Jog brings communities together to get active, get connected and support Australians living with dementia, their families and carers.

 

In 2026, an estimated 113,900 people live with dementia in Victoria. Dementia is now the leading cause of death for Australians, and without significant intervention, the number of Australians living with dementia is expected to increase to more than one million by 2065.

 

In 2026, 14 Memory Walk & Jog events are scheduled nation-wide, giving people across Australia the opportunity to take part. You can find your closest event at memorywalk.com.au/find-an-event.

 

Come together with your community for a fun, family-friendly day where people of all ages and abilities can walk, jog or run to support the 446,500 Australians living with dementia and 1.7 million people involved in their care. Each event is a welcoming space to connect, share stories, and raise much needed funds for Dementia Australia.  

 

As the number of Australians impacted by dementia continues to grow, it is more important than ever that we raise funds and encourage everyone to get active for their brain health.

 

Funds raised through the Ballarat Memory Walk & Jog will help Dementia Australia to deliver vital support services, expand life-changing programs and drive innovative research, helping to bring us closer to a future where dementia no longer impacts Australian families. Get active and show your support, sign-up to participate in Memory Walk & Jog or volunteer at memorywalk.com.au/event/ballarat/home

 

Can’t attend Memory Walk & Jog but want to be involved? Organise your own group or individual walk or jog, with a MyWay event. Choose your own date and location and register at www.memorywalk.com.au/get-involved/mw. 

 

-Ends-

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 446,500 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Molly Bryan Senior Media and Communications Advisor 0457851765 [email protected]

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

Photos and video of previous Memory Walk & Jog events for publication are available for use.

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 16/06/2026
  • 22:47
Optimi Health Corp.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber SchemeVANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products…

  • Medical Health Aged Care
  • 16/06/2026
  • 14:30
Dementia Australia

Brisbane comes together for people impacted by dementia

Brisbane community members tied up their laces and showed up in force last weekend for the 2026 Brisbane Memory Walk & Jog - throwing their support behind people impacted by dementia whilst getting active to improve their brain health. More than 1,470 people walked, ran and jogged to the finish line to raise an impressive total of $195,098. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, volunteered and raised vital funds for the cause. “There was an incredible turnout from the Brisbane community this year yet again, in support of the many people impacted by…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 16/06/2026
  • 09:51
ENA Respiratory

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies. A composition-of-matter patent (US 17/622,451, "A series of TLR2 agonist compounds") and A method-of-use patent for the treatment of rhinovirus-mediated exacerbations of chronic obstructive pulmonary disease (COPD) (US 16/495,829, "Methods of treating rhinovirus-mediated exacerbations of COPD…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.